scholarly journals Typhoid and Paratyphoid Cost of Illness in Nepal: Patient and Health Facility Costs From the Surveillance for Enteric Fever in Asia Project II

2020 ◽  
Vol 71 (Supplement_3) ◽  
pp. S306-S318 ◽  
Author(s):  
Nelly Mejia ◽  
Taiwo Abimbola ◽  
Jason R Andrews ◽  
Krista Vaidya ◽  
Dipesh Tamrakar ◽  
...  
Keyword(s):  
Healthcare Provider ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Enteric Fever ◽  
Healthcare Providers ◽  
Indirect Costs ◽  
Economic Cost ◽  
Prevention Measures ◽  
Illness Onset ◽  
The Cost

Abstract Background Enteric fever is endemic in Nepal and its economic burden is unknown. The objective of this study was to estimate the cost of illness due to enteric fever (typhoid and paratyphoid) at selected sites in Nepal. Methods We implemented a study at 2 hospitals in Nepal to estimate the cost per case of enteric fever from the perspectives of patients, caregivers, and healthcare providers. We collected direct medical, nonmedical, and indirect costs per blood culture–confirmed case incurred by patients and their caregivers from illness onset until after enrollment and 6 weeks later. We estimated healthcare provider direct medical economic costs based on quantities and prices of resources used to diagnose and treat enteric fever, and procedure frequencies received at these facilities by enrolled patients. We collected costs in Nepalese rupees and converted them into 2018 US dollars. Results We collected patient and caregiver cost of illness information for 395 patients, with a median cost of illness per case of $59.99 (IQR, $24.04–$151.23). Median direct medical and nonmedical costs per case represented ~3.5% of annual individual labor income. From the healthcare provider perspective, the average direct medical economic cost per case was $79.80 (range, $71.54 [hospital B], $93.43 [hospital A]). Conclusions Enteric fever can impose a considerable economic burden on patients, caregivers, and health facilities in Nepal. These new estimates of enteric fever cost of illness can improve evaluation and modeling of the costs and benefits of enteric fever–prevention measures.

scholarly journals Typhoid and Paratyphoid Cost of Illness in Bangladesh: Patient and Health Facility Costs From the Surveillance for Enteric Fever in Asia Project II

2020 ◽  
Vol 71 (Supplement_3) ◽  
pp. S293-S305 ◽  
Author(s):  
Nelly Mejia ◽  
Sarah W Pallas ◽  
Samir Saha ◽  
Jamal Udin ◽  
K M Ishtiaque Sayeed ◽  
...  
Keyword(s):  
Cost Of Illness ◽  
Economic Burden ◽  
Enteric Fever ◽  
Unit Cost ◽  
Indirect Costs ◽  
Public Health Policies ◽  
Illness Onset ◽  
Illness Study ◽  
The Cost ◽  
Substantial Economic Burden

Abstract Background We conducted a cost of illness study to assess the economic burden of pediatric enteric fever (typhoid and paratyphoid) in Bangladesh. Results can inform public health policies to prevent enteric fever. Methods The study was conducted at 2 pediatric health facilities in Dhaka. For the patient and caregiver’s perspective, we administered questionnaires on costs incurred from illness onset until the survey dates to caregivers of patients with blood culture positive cases at enrollment and 6 weeks later to estimate the direct medical, direct nonmedical, and indirect costs. From the perspective of the health care provider, we collected data on quantities and prices of resources used by the 2 hospitals to estimate the direct medical economic costs to treat a case of enteric fever. We collected costs in Bangladeshi takas and converted them into 2018 US dollars. We multiplied the unit cost per procedure by the frequency of procedures in the surveillance case cohort to calculate the average cost per case. Results Among the 1772 patients from whom we collected information, the median cost of illness per case of enteric fever from the patient and caregiver perspective was US $64.03 (IQR: US $33.90 –$173.48). Median direct medical and nonmedical costs per case were 3% of annual labor income across the sample. From the perspective of the healthcare provider, the average direct medical cost per case was US $58.64 (range: US $37.25 at Hospital B, US $73.27 at Hospital A). Conclusions Our results show substantial economic burden of enteric fever in Bangladesh, with higher costs for patients receiving inpatient care. As antimicrobial resistance increases globally, the cost of illness could increase, due to more expensive and potent drugs required for treatment.

scholarly journals Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 988
Author(s):  
Ahmed Alghamdi ◽  
Eman Algarni ◽  
Bander Balkhi ◽  
Abdulaziz Altowaijri ◽  
Abdulaziz Alhossan
Keyword(s):  
Heart Failure ◽  
Saudi Arabia ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Indirect Costs ◽  
Health Care Expenditures ◽  
Decision Makers ◽  
Hospitalization Costs ◽  
Illness Study ◽  
The Cost

Heart failure (HF) is considered to be a global health problem that generates a significant economic burden. Despite the growing prevalence in Saudi Arabia, the economic burden of HF is not well studied. The aim of this study was to estimate the health care expenditures associated with HF in Saudi Arabia from a social perspective. We conducted a multicenter cost of illness (COI) study in two large governmental centers in Riyadh, Saudi Arabia using 369 HF patients. A COI model was developed in order to estimate the direct medical costs associated with HF. The indirect costs of HF were estimated based on a human capital approach. Descriptive and inferential statistics were analyzed. The direct medical cost per HF patient was $9563. Hospitalization costs were the major driver in total spending, followed by medication and diagnostics costs. The cost significantly increased in line with the disease progression, ranging from $3671 in class I to $16,447 in class IV. The indirect costs per working HF patient were $4628 due to absenteeism, and $6388 due to presenteeism. The economic burden of HF is significantly high in Saudi Arabia. Decision makers need to focus on allocating resources towards strategies that prevent frequent hospitalizations and improve HF management and patient outcomes in order to lower the growing economic burden.

Abstract 19839: Clinical and Economic Burden of Rheumatic Heart Disease in Low-Income Nations: Estimating the Cost-of-Illness in India and Uganda

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Alexander T Sandhu ◽  
Kathikeyan G ◽  
Ann Bolger ◽  
Emmy Okello ◽  
Dhruv S Kazi
Keyword(s):  
Heart Disease ◽  
Rheumatic Heart Disease ◽  
Cost Of Illness ◽  
Economic Burden ◽  
Indirect Costs ◽  
Medical Costs ◽  
Discrete State ◽  
Direct Medical Costs ◽  
The Cost ◽  
Rheumatic Heart

Introduction: Rheumatic heart disease (RHD) strikes young adults at their peak economic productivity. Defining the global economic burden of RHD may motivate investments in research and prevention, yet prior approaches considering only medical costs may have underestimated the cost of illness. Objectives: To estimate the clinical and economic burden of RHD in India and Uganda. Outcomes were disability-adjusted life years (DALYs), direct medical costs, and indirect costs due to disability and premature mortality (2012 USD). Methods: We used a discrete-state Markov model to simulate the natural history of RHD using country-, age-, and gender-specific estimates from the literature and census data. We estimated direct medical costs from WHO-CHOICE and Disease Control and Prevention 3 publications. We conservatively estimated indirect costs (lost earnings and imputed caregiver costs) from World Bank data using novel economic methods. Results: In 2012, RHD generated 6.1 million DALYs in India and cost USD 10.7 billion (Table 1), including 1.8 billion in direct medical costs and 8.9 billion in indirect costs. During the same period, RHD produced 216,000 DALYs in Uganda, and cost USD 414 million, and, as in India, indirect costs represented the majority (88%) of the cost of illness. In both countries, women accounted for the majority (71-80%) of the DALYs; in Uganda, women bore 75% of the total cost. In sensitivity analyses, higher progression rates for subclinical disease doubled direct costs and DALYs. Conclusion: RHD exacts an enormous toll on the populations of India and Uganda, and its economic burden may be grossly underestimated if indirect costs are not systematically included. Women bear a disproportionate clinical burden from pregnancy-related complications. These results suggest that effective prevention and screening of RHD may represent a sound public health investment, particularly if targeted at high-risk subgroups such as young women.

scholarly journals Typhoid and Paratyphoid Cost of Illness in Pakistan: Patient and Health Facility Costs From the Surveillance for Enteric Fever in Asia Project II

2020 ◽  
Vol 71 (Supplement_3) ◽  
pp. S319-S335 ◽  
Author(s):  
Nelly Mejia ◽  
Farah Qamar ◽  
Mohammad T Yousafzai ◽  
Jamal Raza ◽  
Denise O Garrett ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Provider ◽  
Cost Of Illness ◽  
Care Provider ◽  
Enteric Fever ◽  
Unit Cost ◽  
Control Measures ◽  
Illness Onset ◽  
Provider Perspective ◽  
The Cost

Abstract Background The objective of this study was to estimate the cost of illness from enteric fever (typhoid and paratyphoid) at selected sites in Pakistan. Methods We implemented a cost-of-illness study in 4 hospitals as part of the Surveillance for Enteric Fever in Asia Project (SEAP) II in Pakistan. From the patient and caregiver perspective, we collected direct medical, nonmedical, and indirect costs per case of enteric fever incurred since illness onset by phone after enrollment and 6 weeks later. From the health care provider perspective, we collected data on quantities and prices of resources used at 3 of the hospitals, to estimate the direct medical economic costs to treat a case of enteric fever. We collected costs in Pakistani rupees and converted them into 2018 US dollars. We multiplied the unit cost per procedure by the frequency of procedures in the surveillance case cohort to calculate the average cost per case. Results We collected patient and caregiver information for 1029 patients with blood culture–confirmed enteric fever or with a nontraumatic terminal ileal perforation, with a median cost of illness per case of US $196.37 (IQR, US $72.89–496.40). The median direct medical and nonmedical costs represented 8.2% of the annual labor income. From the health care provider perspective, the estimated average direct medical cost per case was US $50.88 at Hospital A, US $52.24 at Hospital B, and US $11.73 at Hospital C. Conclusions Enteric fever can impose a considerable economic burden in Pakistan. These new estimates of the cost of illness of enteric fever can improve evaluation and modeling of the costs and benefits of enteric fever prevention and control measures, including typhoid conjugate vaccines.

The economic cost of schizophrenia in Ireland: a cost of illness study

2008 ◽  
Vol 25 (3) ◽  
pp. 80-87 ◽  
Author(s):  
Caragh Behan ◽  
Brendan Kennelly ◽  
Eadbhard O'Callaghan
Keyword(s):  
Informal Care ◽  
Cost Of Illness ◽  
Indirect Costs ◽  
Economic Cost ◽  
Premature Mortality ◽  
Illness Study ◽  
Lost Productivity ◽  
Human Cost ◽  
The Cost ◽  
Cost Of Illness Study

AbstractObjectives: Although there are many published reports about the human cost of schizophrenia, there are far fewer estimates of its economic cost, particularly in Ireland. The aim of this study was to provide a prevalence-based estimate of the costs associated with schizophrenia in Ireland during 2006.Method: Using standard Cost of Illness (COI) procedures we compiled data from many sources including the Health Research Board, the Department of Health and Children and other government publications. Costs relating to health and social care, informal care, lost productivity, premature mortality and other public expenditures were included. Where national data were unavailable, we used bottom-up data from a geographically defined catchment area study and, in some instances, costs from two catchment areas were averaged. We did not measure human or intangible costs.Results: The estimated total cost of schizophrenia was €460.6 million in 2006. The direct cost of care was €117.5 million and the burden of indirect costs was €343 million. The cost of lost productivity due to unemployment, absence from work and premature mortality was €277 million. Within indirect costs, the expenditure on informal care borne by families was €43.8 million.Conclusions: Schizophrenia is not a very common condition but is an expensive one. This is attributable to its young age at onset, relatively low mortality rate and high severity particularly in terms of its impact on future employment. Measures to improve outcomes coupled with measures to improve employment such as supported employment strategies may impact significantly on the cost of schizophrenia. The study is limited because the national unit costs of many variables are not directly available and these Irish data are likely to be an underestimate. However, the results are comparable with a 2005 cost of illness study UK study.

scholarly journals Economic burden of eating disorders in South Korea

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Sang Min Lee ◽  
Minha Hong ◽  
Saengryeol Park ◽  
Won Sub Kang ◽  
In-Hwan Oh
Keyword(s):  
Eating Disorders ◽  
South Korea ◽  
Economic Burden ◽  
Indirect Costs ◽  
Economic Cost ◽  
Medical Expenditure ◽  
Treatment Prevalence ◽  
Total Economic Cost ◽  
Total Treatment ◽  
The Cost

Abstract Background Few studies have investigated the epidemiology of eating disorders using national representative data. In this study, we investigated the treatment prevalence and economic burden of eating disorders in South Korea. Methods The aim of this study was to estimate the treatment prevalence and the medical expenditure of diagnosed eating disorders (ICD F50.x) in South Korea between 2010 and 2015. We also examined the economic costs of eating disorders, including the direct medical cost, direct non-medical costs, and indirect costs, in order to calculate the economic burden of such disorders. Results The total treatment prevalence of eating disorders in South Korea was 12.02 people (per 100,000) in 2010, and 13.28 in 2015. The cost of medical expenditures due to eating disorders increased from USD 1229724 in 2010 to USD 1843706 in 2015. The total economic cost of eating disorders was USD 5455626 in 2015. In 2015, the economic cost and prevalence of eating disorders was the highest in the 20–29 age group. Conclusions The results showed the eating disorders are insufficiently managed in the medical insurance system. Further research is therefore warranted to better understand the economic burdens of each type of eating disorder.

scholarly journals Economic burden of eating disorders in South Korea

2020 ◽  
Author(s):  
Sang Min Lee ◽  
Minha Hong ◽  
Saengryeol Park ◽  
Won Sub Kang ◽  
In-Hwan Oh
Keyword(s):  
Eating Disorders ◽  
South Korea ◽  
Economic Burden ◽  
Indirect Costs ◽  
Economic Cost ◽  
Medical Expenditures ◽  
Medical Expenditure ◽  
Total Prevalence ◽  
Total Economic Cost ◽  
The Cost

Abstract BackgroundFew studies have investigated the epidemiology of eating disorders using national representative data. In this study, we investigated the prevalence and economic burden of eating disorders in South Korea.MethodsThe aim of this study was to estimate the medical expenditure of diagnosed eating disorders (ICD F50.x) in South Korea between 2010 and 2015. We also examined the economic costs of eating disorders, including the direct medical cost, direct non-medical costs, and indirect costs, in order to calculate the economic burden of such disorders.ResultsThe total prevalence of eating disorders in South Korea was 12.02 people (per 100 000) in 2010, and 13.28 in 2015. The cost of medical expenditures due to eating disorders increased from USD 1 229 724 in 2010 to USD 1 843 706 in 2015. The total economic cost of eating disorders was USD 5 455 626 in 2015. In 2015, the economic cost and prevalence of eating disorders was the highest in the 20–29 age group.ConclusionsThe results showed the eating disorders are insufficiently managed in the medical insurance system. Further research is therefore warranted to better understand the economic burdens of each type of eating disorder.

scholarly journals National Economic Burden Associated with Management of Periodontitis in Malaysia

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Tuti Ningseh Mohd Dom ◽  
Rasidah Ayob ◽  
Khairiyah Abd Muttalib ◽  
Syed Mohamed Aljunid
Keyword(s):  
Societal Perspective ◽  
Economic Burden ◽  
Census Data ◽  
Adult Population ◽  
National Level ◽  
Indirect Costs ◽  
Treatment Costs ◽  
High Prevalence ◽  
National Economic ◽  
The Cost

Objectives. The aim of this study is to estimate the economic burden associated with the management of periodontitis in Malaysia from the societal perspective.Methods. We estimated the economic burden of periodontitis by combining the disease prevalence with its treatment costs. We estimated treatment costs (with 2012 value of Malaysian Ringgit) using the cost-of-illness approach and included both direct and indirect costs. We used the National Oral Health Survey for Adults (2010) data to estimate the prevalence of periodontitis and 2010 national census data to estimate the adult population at risk for periodontitis.Results. The economic burden of managing all cases of periodontitis at the national level from the societal perspective was approximately MYR 32.5 billion, accounting for 3.83% of the 2012 Gross Domestic Product of the country. It would cost the nation MYR 18.3 billion to treat patients with moderate periodontitis and MYR 13.7 billion to treat patients with severe periodontitis.Conclusion. The economic burden of periodontitis in Malaysia is substantial and comparable with that of other chronic diseases in the country. This is attributable to its high prevalence and high cost of treatment. Judicious application of promotive, preventive, and curative approaches to periodontitis management is decidedly warranted.

scholarly journals Cost of care of chronic non-communicable diseases in Jamaican patients: the role of obesity

2016 ◽  
Vol 17 (2) ◽  
pp. 81-95
Author(s):  
Christine M. Fray-Aiken ◽  
Rainford J. Wilks ◽  
Abdullahi O. Abdulkadri ◽  
Affette M. McCaw-Binns
Keyword(s):  
Cost Of Illness ◽  
Hospital Setting ◽  
Indirect Costs ◽  
Communicable Diseases ◽  
Cost Of Care ◽  
Total Direct Cost ◽  
Non Communicable Diseases ◽  
Female Patients ◽  
Per Capita ◽  
The Cost

OBJECTIVE: To estimate the economic cost of Chronic Non-Communicable Diseases (CNCDs) and the portion attributable to obesity among patients in Jamaica.METHODS: The cost-of-illness approach was used to estimate the cost of care in a hospital setting in Jamaica for type 2 diabetes mellitus, hypertension, coronary heart disease, stroke, gallbladder disease, breast cancer, colon cancer, osteoarthritis, and high cholesterol. Cost and service utilization data were collected from the hospital records of all patients with these diseases who visited the University Hospital of the West Indies (UHWI) during 2006. Patients were included in the study if they were between15 and 74 years of age and if female, were not pregnant during that year. Costs were categorized as direct or indirect. Direct costs included costs for prescription drugs, consultation visits (emergency and clinic visits), hospitalizations, allied health services, diagnostic and treatment procedures. Indirect costs included costs attributed to premature mortality, disability (permanent and temporary), and absenteeism. Indirect costs were discounted at 3% rate.RESULTS: The sample consisted of 554 patients (40%) males (60%) females. The economic burden of the nine diseases was estimated at US$ 5,672,618 (males 37%; females 63%) and the portion attributable to obesity amounted to US$ 1,157,173 (males 23%; females 77%). Total direct cost was estimated at US$ 3,740,377 with female patients accounting for 69.9% of this cost. Total indirect cost was estimated at US$ 1,932,241 with female patients accounting for 50.6% of this cost. The greater cost among women was not found to be statistically significant. Overall, on a per capita basis, males and females accrued similar costs-of-illness (US$ 9,451.75 vs. US$ 10,758.18).CONCLUSIONS: In a country with per capita GDP of less than US$ 5,300, a per capita annual cost of illness of US$ 10,239 for CNCDs is excessive and has detrimental implications for the health and development of Jamaica.

ANALISA COST OF ILLNESS AKIBAT PENGGUNAAN NSAIDS DI SEBUAH APOTEK DI KOTA MEDAN, INDONESIA

2017 ◽  
Vol 1 (1) ◽  
pp. 52
Author(s):  
Hari Ronaldo Tanjung ◽  
Azmi Sarriff ◽  
Urip Harahap
Keyword(s):  
Drug Therapy ◽  
Direct Medical Cost ◽  
Cost Of Illness ◽  
Medical Cost ◽  
Indirect Costs ◽  
Undesirable Event ◽  
Therapeutic Outcomes ◽  
The Cost ◽  
Drug Therapy Problems ◽  
Pharmacy Setting

Background: A drug therapy problem is any undesirable event experienced by a patient which involves, or is suspected to involve drug therapy and that interferes with achieving the desired goals of therapy. Drug Therapy Problems (DTPs) can lead to ineffective pharmacotherapy and may cause drug-related morbidity and mortality.Objective: The study aimed to estimates the direct medical cost of illness caused by the drug morbidity or mortality related to NSAID utilization in a community pharmacy setting at Medan, Indonesia.Method: Thisstudy used 7 (seven) categories probabilities and costs associated with the therapeutic outcomes to estimate the direct medical cost of illness resulting from morbidity related NSAIDs utilization. Direct non medical costs, indirect costs, and intangible costs related to drug-related-morbidity and mortality were not valued in this cost-of-illness analysis.The duration of the study was from July 2009 to October 2010.Result: The patient that experienced NSAIDs-related morbidity estimated to spend Rp.467.848,- each and Rp.11.696.200,- in total to managing the morbidity. Every Rp.1,- spent on NSAIDs therapy, an additional Rp.1,45,- was estimated to spent in managing morbidity related NSAIDs utilization.Conclusion: This result showed the cost of illnessrelated morbidity of NSAIDs utilization exceeds the cost of the medications themselves

Sign in / Sign up

Export Citation Format

Share Document